You are currently viewing the summary.
See the full text- Join / Subscribe
- Buy article
- member account Enable
- Renew subscription
- Recommend a subscription to your library
- Help for librarians
Summary
international Conference on Alzheimer Association in Washington, DC, last week, the researchers expressed cautious optimism that the field is growing. The main reason: alluring advice of two high-profile, Phase II trials of antibodies that latch on β-amyloid, a protein that forms sticky masses in the brain of people with Alzheimer's disease. For some, the small number of people studied and the modest results were far from convincing. But for others at the meeting, the results provide some of the first encouraging evidence that beta-amyloid is a target for treatment. A next step is to try to stimulate the immune defenses of the organism with a vaccine antiamyloid an approach that has failed in the past, but is now getting a second look.
0 Komentar